Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > Gilead

<< Previous

Bullboard Posts

Next >>

Comment by palinc2000on Nov 18, 2020 10:03am

106 Views

Post# 31921555

RE:RE:Gilead

''A third product for a relatively small market""
Why would GILD spend time amd money on drug for which the market is small?
Maybe the market is much larger than what Trogarzos sales have shown so far ,,,,,,I think Levesque is still convinced that this is the case

Wino115 wrote:
So 2 to 3 years away, no safety data yet and will be third product for what appears to be a rather small market. Can't see them wanting to spend a whole lot of time or money on that, but go for it. Thankfully THTX will be well on its way in other more profitable areas by then.

palinc2000 wrote: https://investors.gilead.com/news-releases/news-release-details/gilead-announces-investigational-long-acting-hiv-1-capsid